Covered recipient · General Payments record
JAVIER VASALLO
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$309.63
16 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $309.63 | 16 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $208.10 | 11 |
| E.R. Squibb & Sons, L.L.C. | $35.46 | 2 |
| Janssen Pharmaceuticals, Inc | $26.88 | 1 |
| AstraZeneca Pharmaceuticals LP | $20.85 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.34 | 1 |
Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JAVIER VASALLO
NPI 1376753210 · CMS profile ID 431060
Allopathic & Osteopathic Physicians / Internal Medicine
EL PASO, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1376753210?year=2021&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JAVIER VASALLO, NPI 1376753210, CMS profile ID 431060. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376753210?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). JAVIER VASALLO, NPI 1376753210, CMS profile ID 431060. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376753210?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- JAVIER VASALLO, NPI 1376753210, CMS profile ID 431060, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1376753210?year=2021&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
16 matching records · $309.63 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–16 of 16.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $9.66 | 12/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815028869 | CMS |
| NOVARTIS PHARMACEUTICALS CORPORATION | $18.76 | 12/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815028865 | CMS |
| NOVARTIS PHARMACEUTICALS CORPORATION | $18.63 | 11/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815028861 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.34 | 11/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 850257357 | CMS |
| NOVARTIS PHARMACEUTICALS CORPORATION | $23.87 | 09/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815028857 | CMS |
| Janssen Pharmaceuticals, Inc | $26.88 | 08/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788030845 | CMS |
| NOVARTIS PHARMACEUTICALS CORPORATION | $24.38 | 07/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815028853 | CMS |
| NOVARTIS PHARMACEUTICALS CORPORATION | $21.28 | 06/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815028849 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.85 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829659439 | CMS |
| NOVARTIS PHARMACEUTICALS CORPORATION | $15.00 | 05/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815028845 | CMS |
| NOVARTIS PHARMACEUTICALS CORPORATION | $18.71 | 04/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815028841 | CMS |
| NOVARTIS PHARMACEUTICALS CORPORATION | $15.68 | 04/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815028837 | CMS |
| NOVARTIS PHARMACEUTICALS CORPORATION | $19.08 | 03/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815028829 | CMS |
| NOVARTIS PHARMACEUTICALS CORPORATION | $23.05 | 03/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815028833 | CMS |
| E.R. Squibb & Sons, L.L.C. | $13.82 | 03/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783655265 | CMS |
| E.R. Squibb & Sons, L.L.C. | $21.64 | 03/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783655257 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2021, 2022, 2023, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $335,739.37 | 39 |
| PY2024 | Recipient | $21,043.10 | 2 |
| PY2024 | Principal investigator | $564,577.42 | 59 |
| PY2023 | Recipient | $901.78 | 1 |
| PY2023 | Principal investigator | $812,448.46 | 18 |
| PY2022 | Recipient | $1,101.00 | 1 |
| PY2022 | Principal investigator | $588,022.06 | 6 |
| PY2021 | Principal investigator | $38,744.62 | 4 |
| PY2020 | Principal investigator | $75,173.37 | 8 |
| PY2019 | Principal investigator | $128,348.85 | 16 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
61 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $2,934.00 | 12/16/2024 | Non-covered Recipient Entity Medresearch Inc. | 70033093ACS3003 | No dispute reported | 06/30/2026 | 1078982073 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,267.50 | 11/19/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082444982 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $104.00 | 11/19/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082445160 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,197.00 | 11/18/2024 | Non-covered Recipient Entity Medresearch Inc. | 70033093ACS3003 | No dispute reported | 06/30/2026 | 1078982113 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,879.00 | 11/05/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082443756 |
| Principal investigator 1 | Janssen Research & Development, LLC | $850.00 | 10/14/2024 | Non-covered Recipient Entity Medresearch Inc. | 70033093ACS3003 | No dispute reported | 06/30/2026 | 1078982097 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $555.00 | 10/09/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082440418 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $210.00 | 10/09/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082440420 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $765.00 | 10/09/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082440422 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $615.00 | 10/09/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082440424 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $300.00 | 10/09/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082440426 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $150.00 | 10/09/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082440428 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,618.75 | 10/09/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082440430 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.00 | 10/09/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082440432 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,230.00 | 10/09/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082440434 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,117.50 | 10/09/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082440436 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.00 | 10/09/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082440438 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $104.00 | 10/09/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082440440 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $127.00 | 10/09/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082440442 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $208.00 | 10/09/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082440444 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $104.00 | 10/09/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082440446 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $350.00 | 10/08/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082440314 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $208.00 | 10/08/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082440316 |
| Principal investigator 1 | Janssen Research & Development, LLC | $50.00 | 10/07/2024 | Non-covered Recipient Entity Medresearch Inc. | 70033093ACS3003 | No dispute reported | 06/30/2026 | 1078982095 |
| Recipient | Eli Lilly and Company | $16,784.37 | 09/24/2024 | Covered Recipient Physician | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1137347635 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $300.00 | 09/24/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082439256 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,475.00 | 09/24/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082439260 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $208.00 | 09/24/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082439274 |
| Recipient | Eli Lilly and Company | $4,258.73 | 09/23/2024 | Covered Recipient Physician | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1137347803 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,276.00 | 09/20/2024 | Non-covered Recipient Entity Medresearch Inc. | 70033093ACS3003 | No dispute reported | 06/30/2026 | 1078982119 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $225.00 | 09/05/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082436626 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $150.00 | 09/05/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082436628 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 09/05/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082436630 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.00 | 09/05/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082436632 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $156.00 | 09/05/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082436634 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $104.00 | 09/05/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082436636 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,855.00 | 09/05/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082436638 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,422.00 | 09/05/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082436640 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,003.00 | 08/21/2024 | Non-covered Recipient Entity Medresearch Inc. | 70033093ACS3003 | No dispute reported | 06/30/2026 | 1078982107 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,146.00 | 07/24/2024 | Non-covered Recipient Entity Medresearch Inc. | 70033093ACS3003 | No dispute reported | 06/30/2026 | 1078982075 |
| Principal investigator 1 | Janssen Research & Development, LLC | $235.00 | 07/10/2024 | Non-covered Recipient Entity Medresearch Inc. | 70033093ACS3003 | No dispute reported | 06/30/2026 | 1078982081 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,109.00 | 06/17/2024 | Non-covered Recipient Entity Medresearch Inc. | 70033093ACS3003 | No dispute reported | 06/30/2026 | 1078982117 |
| Principal investigator 1 | Janssen Research & Development, LLC | $285.00 | 05/24/2024 | Non-covered Recipient Entity Medresearch Inc. | 70033093ACS3003 | No dispute reported | 06/30/2026 | 1078982085 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,185.00 | 04/26/2024 | Non-covered Recipient Entity Medresearch Inc. | 70033093ACS3003 | No dispute reported | 06/30/2026 | 1078982065 |
| Principal investigator 1 | Eli Lilly and Company | $187.21 | 04/23/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1137362759 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,125.00 | 04/19/2024 | Non-covered Recipient Entity Medresearch Inc. | 70033093ACS3003 | No dispute reported | 06/30/2026 | 1078982111 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,212.00 | 03/22/2024 | Non-covered Recipient Entity Medresearch Inc. | 70033093ACS3003 | No dispute reported | 06/30/2026 | 1078982101 |
| Principal investigator 1 | Eli Lilly and Company | $22,467.12 | 03/18/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1137362367 |
| Principal investigator 1 | Janssen Research & Development, LLC | $40.00 | 03/13/2024 | Non-covered Recipient Entity Medresearch Inc. | 70033093ACS3003 | No dispute reported | 06/30/2026 | 1078982063 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $16,394.70 | 03/06/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1110838148 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,660.00 | 02/23/2024 | Non-covered Recipient Entity Medresearch Inc. | 70033093ACS3003 | No dispute reported | 06/30/2026 | 1078982105 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,185.00 | 02/21/2024 | Non-covered Recipient Entity Medresearch Inc. | 70033093ACS3003 | No dispute reported | 06/30/2026 | 1078982079 |
| Principal investigator 1 | Janssen Research & Development, LLC | $30.00 | 02/14/2024 | Non-covered Recipient Entity Medresearch Inc. | 70033093ACS3003 | No dispute reported | 06/30/2026 | 1078982067 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $58,203.25 | 02/13/2024 | Non-covered Recipient Entity MEDRESEARCH INC MEDRESEARCH INC DBA EL PASO MEDICAL RESEARCH INSTITUTE | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1089693495 |
| Principal investigator 1 | Janssen Research & Development, LLC | $100.00 | 02/02/2024 | Non-covered Recipient Entity Medresearch Inc. | 70033093ACS3003 | No dispute reported | 06/30/2026 | 1078982089 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $210,679.94 | 01/31/2024 | Non-covered Recipient Entity MED RESEARCH INC | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1089689817 |
| Principal investigator 1 | Eli Lilly and Company | $431.25 | 01/25/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1137361879 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,504.00 | 01/19/2024 | Non-covered Recipient Entity Medresearch Inc. | 70033093ACS3003 | No dispute reported | 06/30/2026 | 1078982121 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $12,200.00 | 01/16/2024 | Non-covered Recipient Entity MEDRESEARCH INC MEDRESEARCH INC DBA EL PASO MEDICAL RESEARCH INSTITUTE | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1089693707 |
| Principal investigator 1 | Eli Lilly and Company | $47,806.73 | 01/08/2024 | Non-covered Recipient Entity MEDRESEARCH INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1137362923 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $131,121.47 | 01/01/2024 | Non-covered Recipient Entity MED RESEARCH INC | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1089684727 |